Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Cerdulatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Portola Presents New Interim Data from Ongoing Phase 2a Study Cerdulatinib
    Portola Presents New Interim Data from Ongoing Phase 2a Study Cerdulatinib

    09 Dec 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/portola-pharmaceuticals-presents-new-interim-data-from-ongoing-phase-2a-study-of-its-oral-sykjak-inhibitor-cerdulatinib-in-heavily-pre-treated-t-cell-malignancies-300971014.html

    PR NEWSWIRE
    09 Dec 2019
    Share Share
    Dermavant Announces 1st Patient Dosed in Phase 2a Clinical Trial of Cerdulatinib
    Dermavant Announces 1st Patient Dosed in Phase 2a Clinical Trial of Cerdulatinib

    03 Dec 2019

    // GLOBE NEWSWIRE

    https://www.globenewswire.com/news-release/2019/12/03/1955483/0/en/Dermavant-Announces-First-Patient-Dosed-in-Phase-2a-Clinical-Trial-of-Topical-Dual-JAK-Syk-Inhibitor-Cerdulatinib-for-Vitiligo.html

    GLOBE NEWSWIRE
    03 Dec 2019
    Share Share
    Portola Pharmaceuticals R&D Exec to Retire
    Portola Pharmaceuticals R&D Exec to Retire

    24 Apr 2019

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2019/04/24/1808762/0/en/Portola-Pharmaceuticals-Announces-Retirement-of-Dr-John-Curnutte-Executive-Vice-President-and-Head-of-Research-and-Development.html

    GLOBENEWSWIRE
    24 Apr 2019
    Share Share
    Dermavant hires Todd Zavodnick as CEO
    Dermavant hires Todd Zavodnick as CEO

    15 Nov 2018

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/dermavant-hires-todd-zavodnick-as-ceo

    Nick Paul Taylor FIERCE BIOTECH
    15 Nov 2018
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.